SHA: 600276

Explore the latest insights on SHA: 600276 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SHA: 600276’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that its partner AstraZeneca plc (NYSE: AZN) has submitted a New Drug Application (NDA) to the U.S. FDA for the combination therapy…

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase Ib/III Study of Dalpiciclib in mHSPC

CompanyDrug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

CompanyDrug

Jiangsu Hengrui Submits Market Approval Filing for SHR0302 in Ankylosing Spondylitis

Show More